Mathews Journal of Pharmaceutical Science

2474-753X

Previous Issues Volume 9, Issue 2 - 2025

Development and Optimization of Mesembrine Nanoliposome

K Ravi Kumar*, B Ravindra Babu, Rashmi Rani Das

Pulla Reddy Institute of Pharmacy, Hyderabad, India

*Corresponding author: Dr. K Ravi Kumar, Pulla Reddy Institute of Pharmacy, Department of Pharmaceutics, Domadugu, Gummadidala (M), Sangareddy District, Telangana State, India, Email: [email protected]

Received Date: January 02, 2025

Published Date: March 12, 2025

Citation: Ravi Kumar K, et al. (2025). Development and Optimization of Mesembrine Nanoliposome. Mathews J Pharma Sci. 9(2):46.

Copyrights: Ravi Kumar K, et al. © (2025).

ABSTRACT

This study focuses on the development and optimization of nanoliposomal formulations of mesembrine for effective brain-targeted drug delivery. Mesembrine, a potent serotonin reuptake inhibitor, is explored for its therapeutic potential in treating depression. Nanoliposomes were chosen as the delivery system due to their ability to enhance drug stability, reduce side effects, and improve brain bioavailability by bypassing the blood-brain barrier. The formulation was optimized using the thin-film hydration method, with parameters like particle size, zeta potential, and encapsulation efficiency meticulously evaluated. Preformulation studies confirmed mesembrine’s stability and compatibility with excipients. The optimized formulation demonstrated high drug entrapment efficiency and sustained drug release. In vitro evaluations suggested improved pharmacokinetics compared to conventional formulations. This research highlights the potential of nanotechnology in advancing therapeutic outcomes for central nervous system disorders. Future work will focus on in vivo studies and clinical trials to validate these finding.

Keywords: Mesembrine, Nanoliposomes, Brain-Targeted Drug Delivery, Depression Treatment, Blood-Brain Barrier, Nanotechnology.


Creative Commons License

© 2015 Mathews Open Access Journals. All Rights Reserved.

Open Access by Mathews Open Access Journals is licensed under a
Creative Commons Attribution 4.0 International License.
Based On a Work at Mathewsopenaccess.com